RXi Pharmaceuticals, a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering therapeutic platform, has entered into a research collaboration with the Karolinska Institutet in Stockholm, Sweden. This collaboration will explore RXi’s sd-rxRNA compounds against targets involved in T cell and NK cell differentiation and/or in the immune cell tumor-induced stress response with the…